Daiichi Sankyo Co., Ltd. (4568)

4,536.0 -26.0 (-0.57%)
Close JPY Disclaimer

Daiichi Sankyo Co., Ltd. Company Profile

Equity Type
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer’s disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Contact Information
Tokyo,103-8426 Japan
81 3 6225 1111
Top Executives
Noritaka Uji 72 2014 Independent Outside Chairman
Sunao Manabe 67 2009 President, Group CEO & Representative Director
Hiroyuki Okuzawa 60 2018 Senior Executive Officer, Global Head of Corporate Planning & Management Div., CFO and Director
Masahiko Ohtsuki 63 2014 Senior Executive Officer, Global Head of Digital Transformation Management Div., CIO & Director
Kazuaki Kama 74 2019 Independent Outside Director
Sawako Nohara 64 2019 Independent Outside Director
Takashi Fukuoka 0 2022 Executive Officer, Global Head of Corporate Strategy Division & Director
Ryoichi Watanabe 64 2019 Member of Audit & Supervisory Board
Masako Watanabe 60 2021 Outside Audit & Supervisory Board Member
Shoji Hirashima 61 2017 Senior Executive Officer, Head of Japan Business Unit & Director
Yasuhiro Komatsu 0 2022 Independent Outside Director
Kenji Sato 59 2019 Member of Audit & Supervisory Board
Yukiko Imazu 54 2018 Outside Independent Audit & Supervisory Board Member
Mitsuhiro Matsumoto 61 2022 Outside Independent Audit & Supervisory Board Member
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles